CD274 and neoplasm: This is an effective complement to tumor PD-L1 and soluble PD-L1 to identify patients who may benefit from immunotherapy and to dynamically monitor therapeutic response (Chen G. et al., 2018; Theodoraki et al., 2019; Cordonnier et al., 2020; Daassi et al., 2020).